Intact Investment Management Inc. Takes $3.57 Million Position in Gilead Sciences (GILD)

Intact Investment Management Inc. acquired a new stake in Gilead Sciences (NASDAQ:GILD) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 47,400 shares of the biopharmaceutical company’s stock, valued at approximately $3,573,000.

Several other large investors have also recently bought and sold shares of GILD. Heritage Wealth Advisors increased its position in Gilead Sciences by 2.5% during the fourth quarter. Heritage Wealth Advisors now owns 26,523 shares of the biopharmaceutical company’s stock worth $1,903,000 after purchasing an additional 642 shares during the last quarter. Hanson & Doremus Investment Management increased its position in Gilead Sciences by 35.7% during the fourth quarter. Hanson & Doremus Investment Management now owns 2,461 shares of the biopharmaceutical company’s stock worth $176,000 after purchasing an additional 648 shares during the last quarter. Griffin Asset Management Inc. increased its position in Gilead Sciences by 2.5% during the fourth quarter. Griffin Asset Management Inc. now owns 27,160 shares of the biopharmaceutical company’s stock worth $1,946,000 after purchasing an additional 650 shares during the last quarter. First Capital Advisors Group LLC. increased its position in Gilead Sciences by 9.1% during the fourth quarter. First Capital Advisors Group LLC. now owns 7,857 shares of the biopharmaceutical company’s stock worth $563,000 after purchasing an additional 653 shares during the last quarter. Finally, Wedbush Securities Inc. increased its position in Gilead Sciences by 1.0% during the fourth quarter. Wedbush Securities Inc. now owns 65,102 shares of the biopharmaceutical company’s stock worth $4,664,000 after purchasing an additional 660 shares during the last quarter. 77.72% of the stock is owned by institutional investors and hedge funds.

In other Gilead Sciences news, Director John Francis Cogan sold 5,833 shares of the stock in a transaction on Monday, March 12th. The shares were sold at an average price of $80.93, for a total transaction of $472,064.69. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Gregg H. Alton sold 25,000 shares of the stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $78.69, for a total transaction of $1,967,250.00. Following the transaction, the executive vice president now owns 69,426 shares in the company, valued at $5,463,131.94. The disclosure for this sale can be found here. Insiders have sold a total of 226,667 shares of company stock worth $17,060,854 over the last quarter. 1.16% of the stock is currently owned by insiders.

Shares of Gilead Sciences opened at $67.83 on Wednesday, MarketBeat Ratings reports. The firm has a market capitalization of $87.94 billion, a PE ratio of 7.92, a PEG ratio of -5.88 and a beta of 1.19. The company has a quick ratio of 2.75, a current ratio of 2.84 and a debt-to-equity ratio of 1.32. Gilead Sciences has a twelve month low of $63.76 and a twelve month high of $89.54.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, May 1st. The biopharmaceutical company reported $1.48 earnings per share for the quarter, missing the consensus estimate of $1.67 by ($0.19). The firm had revenue of $5.09 billion during the quarter, compared to analysts’ expectations of $5.40 billion. Gilead Sciences had a net margin of 14.03% and a return on equity of 45.49%. Gilead Sciences’s revenue for the quarter was down 21.8% compared to the same quarter last year. During the same quarter last year, the company posted $2.23 earnings per share. research analysts predict that Gilead Sciences will post 5.75 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 28th. Shareholders of record on Friday, June 15th will be paid a dividend of $0.57 per share. The ex-dividend date of this dividend is Thursday, June 14th. This represents a $2.28 dividend on an annualized basis and a yield of 3.36%. Gilead Sciences’s dividend payout ratio (DPR) is 26.64%.

Several equities analysts recently commented on the stock. Vetr raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.25 price target for the company in a research report on Monday, February 5th. Leerink Swann decreased their price objective on shares of Gilead Sciences from $86.00 to $83.00 and set a “market perform” rating for the company in a research note on Wednesday, February 7th. Maxim Group set a $94.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Tuesday, February 6th. Citigroup reiterated a “buy” rating and set a $105.00 price objective (up from $103.00) on shares of Gilead Sciences in a research note on Thursday, February 8th. Finally, Bank of America boosted their price objective on shares of Gilead Sciences from $82.00 to $87.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 7th. One research analyst has rated the stock with a sell rating, ten have given a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $88.14.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply